4.8 Article

A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote Sonic Hedgehog medulloblastoma

期刊

ONCOGENE
卷 36, 期 43, 页码 5969-5984

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2017.208

关键词

-

资金

  1. National Health and Medical Research Council [APP1046174]
  2. Australian Postgraduate Award
  3. Alex's Lemonade Stand
  4. CERN foundation
  5. Pediatric Brain Tumor Foundation
  6. National Institutes of Health [R01CA159859, R01CA148699]

向作者/读者索取更多资源

Sonic Hedgehog (SHH) signaling at primary cilia drives the proliferation and progression of a subset of medulloblastomas, the most common malignant paediatric brain tumor. Severe side effects associated with conventional treatments and resistance to targeted therapies has led to the need for new strategies. SHH signaling is dependent on primary cilia for signal transduction suggesting the potential for cilia destabilizing mechanisms as a therapeutic target. INPP5E is an inositol polyphosphate 5-phosphatase that hydrolyses PtdIns(4,5)P-2 and more potently, the phosphoinositide (PI) 3-kinase product PtdIns(3,4,5)P-3. INPP5E promotes SHH signaling during embryonic development via PtdIns(4,5)P-2 hydrolysis at cilia, that in turn regulates the cilia recruitment of the SHH suppressor GPR161. However, the role INPP5E plays in cancer is unknown and the contribution of PI3-kinase signaling to cilia function is little characterized. Here, we reveal INPP5E promotes SHH signaling in SHH medulloblastoma by negatively regulating a cilia-compartmentalized PI3-kinase signaling axis that maintains primary cilia on tumor cells. Conditional deletion of Inpp5e in a murine model of constitutively active Smoothened-driven medulloblastoma slowed tumor progression, suppressed cell proliferation, reduced SHH signaling and promoted tumor cell cilia loss. PtdIns(3,4,5)P-3, its effector pAKT and the target pGSK3 beta, which when non-phosphorylated promotes cilia assembly/stability, localized to tumor cell cilia. The number of PtdIns(3,4,5)P-3/pAKT/pGSK3 beta-positive cilia was increased in cultured Inpp5e-null tumor cells relative to controls. PI3-kinase inhibition or expression of wild-type, but not catalytically inactive HA-INPP5E partially rescued cilia loss in Inpp5e-null tumor cells in vitro. INPP5E mRNA and copy number were reduced in human SHH medulloblastoma compared to other molecular subtypes and consistent with the murine model, reduced INPP5E was associated with improved overall survival. Therefore our study identifies a compartmentalized PtdIns(3,4,5)P-3/AKT/GSK3 beta signaling axis at cilia in SHH-dependent medulloblastoma that is regulated by INPP5E to maintain tumor cell cilia, promote SHH signaling and thereby medulloblastoma progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Oncology

Less treatment for Wingless medulloblastoma: germline data re-emphasize this

Anirban Das, Vijay Ramaswamy

NEURO-ONCOLOGY (2020)

Article Oncology

Minimizing General Anesthetic Use in Pediatric Radiation Therapy

Stephanie M. Ntoukas, Tatiana Ritchie, Susan Awrey, David C. Hodgson, Normand Laperriere, Ryan Yee, Vijay Ramaswamy, Barbara-Ann Millar, Nathan Becker, Derek S. Tsang

PRACTICAL RADIATION ONCOLOGY (2020)

Review Oncology

Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy

Chantel Cacciotti, Adam Fleming, Vijay Ramaswamy

JOURNAL OF PATHOLOGY (2020)

Editorial Material Oncology

Medulloblastoma (cross)talk through extracellular vesicles

Liana Nobre, Vijay Ramaswamy

NEURO-ONCOLOGY (2021)

Editorial Material Oncology

Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?

Vijay Ramaswamy, Ute Bartels

NEURO-ONCOLOGY (2021)

Letter Oncology

A novel central nervous system embryonal tumor successfully treated with multi-modal therapy highlights limitation of methylation-based tumor classification

Ritu Lamichhane, Paromita Roy, Cynthia Hawkins, Lateef Zameer, Anisha Gehani, Rimpa B. Achari, Ben Ho, Annie Huang, Uri Tabori, Vijay Ramaswamy, Reghu K. Sukumaran, Anirban Das

PEDIATRIC BLOOD & CANCER (2022)

Editorial Material Oncology

WNT Medulloblastoma Limbo: How Low Can We Go?

Marc Remke, Vijay Ramaswamy

Summary: This article discusses the treatment of pediatric medulloblastoma and highlights the substantial long-term sequelae despite improved survival rates. It raises the question of how to safely de-escalate therapy without compromising its effectiveness.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

How do we approach the management of medulloblastoma in young children?

Lucie Lafay-Cousin, Lorena Baroni, Vijay Ramaswamy, Eric Bouffet

Summary: Therapeutic strategies for young children with medulloblastoma are evolving, including high-dose chemotherapy with stem cell rescue and intraventricular chemotherapy. Studies on different molecular subgroups show excellent survival rates for sonic hedgehog medulloblastoma patients, while those with high-risk features may require innovative therapies.

PEDIATRIC BLOOD & CANCER (2022)

Editorial Material Oncology

Postmortem Tissue Donation: Giving Families the Ability to Choose

Beth Frenkel, Elena Gerasimov, Allen Gustafson, Patti Gustafson, Ginny McLean, Aloysius Ochasi, Angela Waanders, Vijay Ramaswamy

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

The Burden of Surviving Childhood Medulloblastoma: A Population-Based, Matched Cohort Study in Ontario, Canada

Hallie Coltin, Priscila Pequeno, Ning Liu, Derek S. Tsang, Sumit Gupta, Michael D. Taylor, Eric Bouffet, Paul C. Nathan, Vijay Ramaswamy

Summary: This study characterized the late effects of childhood medulloblastoma survivors using real-world health services data. The findings reveal significant long-term medical sequelae and increased mortality rates, emphasizing the need for a re-evaluation of current treatment approaches and prioritization of interventions targeting late effects.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study

Craig Erker, Martin Mynarek, Simon Bailey, Claire M. Mazewski, Lorena Baroni, Maura Massimino, Juliette Hukin, Dolly Aguilera, Andrea M. Cappellano, Vijay Ramaswamy, Alvaro Lassaletta, Sebastien Perreault, Cassie N. Kline, Revathi Rajagopal, George Michaiel, Michal Zapotocky, Vicente Santa-Maria Lopez, Andres Morales La Madrid, Chantel Cacciotti, Eric S. Sandler, Lindsey M. Hoffman, Darren Klawinski, Sara Khan, Ralph Salloum, Anna L. Hoppmann, Valerie Larouche, Kathleen Dorris, Helen Toledano, Stephen W. Gilheeney, Mohamed S. Abdelbaki, Beverly Wilson, Derek S. Tsang, Jeffrey Knipstein, Michal Yalon Oren, Shafqat Shah, Jeffrey C. Murray, Kevin F. Ginn, Zhihong J. Wang, Gudrun Fleischhack, Denise Obrecht, Svenja Tonn, Virginia L. Harrod, Kara Matheson, Bruce Crooks, Douglas R. Strother, Kenneth J. Cohen, Jordan R. Hansford, Sabine Mueller, Ashley Margol, Amar Gajjar, Girish Dhall, Jonathan L. Finlay, Paul A. Northcott, Stefan Rutkowski, Steven C. Clifford, Giles Robinson, Eric Bouffet, Lucie Lafay-Cousin

Summary: The purpose of this study was to assess salvage strategies and prognostic features of patients with infant and young childhood medulloblastoma (iMB) who relapse after craniospinal irradiation (CSI)-sparing therapy. The results showed that the 3-year postrelapse survival rate for patients treated with curative intent was 52.4%. Salvage radiotherapy and chemotherapy might be beneficial for a subset of patients. Therefore, CSI-sparing therapy can be effective in a substantial proportion of relapsed iMB patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome

Anna S. Kolodziejczak, Lea Guerrini-Rousseau, Julien Masliah Planchon, Jonas Ecker, Florian Selt, Martin Mynarek, Denise Obrecht, Martin Sill, Robert J. Autry, Eric Stutheit-Zhao, Steffen Hirsch, Elsa Amouyal, Christelle Dufour, Olivier Ayrault, Jacob Torrejon, Sebastian M. Waszak, Vijay Ramaswamy, Virve Pentikainen, Haci Ahmet Demir, Steven C. Clifford, Ed C. Schwalbe, Luca Massimi, Matija Snuderl, Kristyn Galbraith, Matthias A. Karajannis, Katherine Hill, Bryan K. Li, Mike Walsh, Christine L. White, Shelagh Redmond, Loizou Loizos, Marcus Jakob, Uwe R. Kordes, Irene Schmid, Julia Hauer, Claudia Blattmann, Maria Filippidou, Gianluca Piccolo, Wolfram Scheurlen, Ahmed Farrag, Kerstin Grund, Christian Sutter, Torsten Pietsch, Stephan Frank, Denis M. Schewe, David Malkin, Myriam Ben-Arush, Astrid Sehested, Tai-Tong Wong, Kuo-Sheng Wu, Yen-Lin Liu, Fernando Carceller, Sabine Mueller, Schuyler Stoller, Michael D. Taylor, Uri Tabori, Eric Bouffet, Marcel Kool, Felix Sahm, Andreas von Deimling, Andrey Korshunov, Katja von Hoff, Christian P. Kratz, Dominik Sturm, David T. W. Jones, Stefan Rutkowski, Cornelis M. van Tilburg, Olaf Witt, Gaelle Bougeard, Kristian W. Pajtler, Stefan M. Pfister, Franck Bourdeaut, Till Milde

Summary: This retrospective cohort study investigated medulloblastoma in Li-Fraumeni syndrome (LFS) patients and found poor prognosis. The results showed that patients who received radiotherapy and chemotherapy had better clinical outcomes, while chemotherapy intensity did not affect their prognosis.

NEURO-ONCOLOGY (2023)

Article Cell Biology

Cross-species analysis of SHH medulloblastoma models reveals significant inhibitory effects of trametinib on tumor progression

Stephanie Borlase, Alexandria Decarlo, Ludivine Coudiere-Morrison, Lisa Liang, Christopher J. Porter, Vijay Ramaswamy, Tamra E. Werbowetski-Ogilvie

Summary: This study conducted preclinical testing of the MEK inhibitor trametinib on Sonic Hedgehog (SHH) medulloblastomas. The results showed that trametinib effectively reduced tumor properties, such as tumorsphere size, cell proliferation, viability, and migration. RNA-sequencing further confirmed these findings and revealed changes in gene expression related to cell cycle, stem cell pathways, and SHH signaling. The study also demonstrated that trametinib decreased tumor growth and increased survival in vivo. However, long-term MEK inhibition led to compensatory molecular changes in the IL6/JAK STAT3 and TNF & alpha;/NF & kappa;B signaling pathways. Overall, these findings suggest that trametinib could be a potential targeted therapy for SHH medulloblastomas with elevated MAPK pathway activity.

CELL DEATH DISCOVERY (2023)

Article Oncology

Abnormalities of structural brain connectivity in pediatric brain tumor survivors

Adeoye Oyefiade, Iska Moxon-Emre, Kiran Beera, Eric Bouffet, Michael Taylor, Vijay Ramaswamy, Suzanne Laughlin, Jovanka Skocic, Donald J. Mabbott

Summary: The study found that there was greater segregation of WM networks after radiotherapy (RT), but no significant network differences were observed between patients treated with or without RT.

NEURO-ONCOLOGY ADVANCES (2022)

Article Oncology

Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country

Nisreen Amayiri, Maisa Swaidan, Ahmed Ibrahimi, Nader Hirmas, Awni Musharbash, Eric Bouffet, Maysa Al-Hussaini, Vijay Ramaswamy

Summary: The study found that in low- to middle-income countries, patients with SHH and group 4 medulloblastoma had survival rates comparable to high-income countries, highlighting the importance of compliance with treatment protocols and avoiding treatment delays for patient survival.

JCO GLOBAL ONCOLOGY (2021)

暂无数据